EP1303303A4 - Immunomodulatory human mhc class ii antigen-binding polypeptides - Google Patents

Immunomodulatory human mhc class ii antigen-binding polypeptides

Info

Publication number
EP1303303A4
EP1303303A4 EP01937390A EP01937390A EP1303303A4 EP 1303303 A4 EP1303303 A4 EP 1303303A4 EP 01937390 A EP01937390 A EP 01937390A EP 01937390 A EP01937390 A EP 01937390A EP 1303303 A4 EP1303303 A4 EP 1303303A4
Authority
EP
European Patent Office
Prior art keywords
antigen
mhc class
binding polypeptides
human mhc
immunomodulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01937390A
Other languages
German (de)
French (fr)
Other versions
EP1303303A1 (en
Inventor
Zoltan Nagy
Michael Tesar
Elisabeth Thomassen-Wolf
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Agennix AG
Original Assignee
Morphosys AG
Agennix AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG, Agennix AG filed Critical Morphosys AG
Priority to EP01937390A priority Critical patent/EP1303303A4/en
Publication of EP1303303A1 publication Critical patent/EP1303303A1/en
Publication of EP1303303A4 publication Critical patent/EP1303303A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP01937390A 2000-05-12 2001-05-14 Immunomodulatory human mhc class ii antigen-binding polypeptides Withdrawn EP1303303A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01937390A EP1303303A4 (en) 2000-05-12 2001-05-14 Immunomodulatory human mhc class ii antigen-binding polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP00110063A EP1156062A1 (en) 2000-05-12 2000-05-12 Immunomodulatory human MHC class II antigen-binding peptides/proteins
EP00110063 2000-05-12
US23876200P 2000-10-06 2000-10-06
US238762P 2000-10-06
PCT/US2001/015626 WO2001087338A1 (en) 2000-05-12 2001-05-14 Immunomodulatory human mhc class ii antigen-binding polypeptides
EP01937390A EP1303303A4 (en) 2000-05-12 2001-05-14 Immunomodulatory human mhc class ii antigen-binding polypeptides

Publications (2)

Publication Number Publication Date
EP1303303A1 EP1303303A1 (en) 2003-04-23
EP1303303A4 true EP1303303A4 (en) 2009-06-10

Family

ID=8168690

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00110063A Withdrawn EP1156062A1 (en) 2000-05-12 2000-05-12 Immunomodulatory human MHC class II antigen-binding peptides/proteins
EP01937390A Withdrawn EP1303303A4 (en) 2000-05-12 2001-05-14 Immunomodulatory human mhc class ii antigen-binding polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP00110063A Withdrawn EP1156062A1 (en) 2000-05-12 2000-05-12 Immunomodulatory human MHC class II antigen-binding peptides/proteins

Country Status (7)

Country Link
EP (2) EP1156062A1 (en)
JP (1) JP2004500847A (en)
CN (1) CN100478029C (en)
AU (2) AU6313301A (en)
CA (1) CA2408513A1 (en)
RU (2) RU2002129930A (en)
WO (1) WO2001087338A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228957B1 (en) * 2001-07-02 2013-07-29 Aimsco Ltd Use anti-hla-antibody for production of pharmaceutical compotisions for the treatment of diseases involving prolierative immune response
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7262278B2 (en) 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
CN103739706B (en) 2002-05-22 2015-11-18 艾斯巴技术-诺华有限责任公司 Immunoglobulin frameworks and the authentication method thereof of the stability of enhancing is shown in born of the same parents' environment
FR2844455B1 (en) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
CA2612417A1 (en) * 2005-06-17 2006-12-28 Biogen Idec Ma Inc. Anti-gfralpha3 antibodies
PL2173379T3 (en) 2007-07-02 2016-02-29 Oncomed Pharm Inc Compositions and methods for treating and diagnosing cancer
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
AU2011218228B2 (en) * 2010-02-17 2015-05-28 One Lambda, Inc. Compositions and methods for the detection of antibodies to native human leukocyte antigen
WO2013012747A1 (en) 2011-07-15 2013-01-24 Oncomed Pharmaceuticals, Inc. Rspo binding agents and uses thereof
EP2855666B1 (en) 2012-05-25 2019-12-04 Cellectis Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
WO2014012007A2 (en) 2012-07-13 2014-01-16 Oncomed Pharmaceuticals, Inc. Rspo3 binding agents and uses thereof
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
EP3193935A4 (en) 2014-09-16 2018-03-21 Oncomed Pharmaceuticals, Inc. Treatment of fibrotic diseases
CN112926883B (en) * 2021-03-29 2023-10-13 中国人民解放军总医院 Lighting effect detection method and system for shelter hospital
EP4147716A1 (en) * 2021-09-10 2023-03-15 Samatva Research Corporation Anti-virus moiety immobilised in a matrix

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017874A1 (en) * 1994-12-07 1996-06-13 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
CA2229043C (en) * 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017874A1 (en) * 1994-12-07 1996-06-13 F. Hoffmann-La Roche Ag Monoclonal antibody fragments having immunosuppressant activity

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. KNAPPIK ET AL.: "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides.", JOURNAL OF MOLECULAR BIOLOGY, vol. 296, 2000, pages 57 - 86, XP004461525 *
D. VIDOVIC ET AL.: "Down-regulation of class II major histocompatibility complex molecules on antigen-presenting cells by antibody fragments.", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 25, no. 12, December 1995 (1995-12-01), Germany, pages 3349 - 3355, XP000564479 *
D. VIDOVIC ET AL.: "Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody.", CANCER LETTERS, vol. 128, 1998, New York, NY, USA, pages 127 - 135, XP002944554 *
H. VIKEN ET AL.: "Serologic subtyping of HLA-DR8 by means of the cytotoxic human monoclonal antibody 5643.", HUMAN IMMUNOLOGY, vol. 43, no. 3, July 1995 (1995-07-01), USA, pages 200 - 206, XP000939101 *
H. VIKEN ET AL.: "The cytotoxic HLA-DQ3 reactive human hybridoma antibody 4166 that may distinguish DQ7+8 from DQ9.", HUMAN IMMUNOLOGY, vol. 42, no. 4, 1995, USA, pages 281 - 288, XP002524443 *
R. EFROS ET AL.: "A human-human hybridoma secreting anti-HLA class II antibody.", THE JOURNAL OF IMMUNOLOGY, vol. 137, no. 5, 1 September 1986 (1986-09-01), Germany, pages 1599 - 1603, XP002524442 *
See also references of WO0187338A1 *
Z. NAGY ET AL.: "Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), USA, pages 801 - 807, XP002432676 *

Also Published As

Publication number Publication date
CA2408513A1 (en) 2001-11-22
JP2004500847A (en) 2004-01-15
AU2001263133B2 (en) 2006-08-10
CN1460025A (en) 2003-12-03
CN100478029C (en) 2009-04-15
AU6313301A (en) 2001-11-26
RU2002129930A (en) 2004-05-10
WO2001087338A1 (en) 2001-11-22
EP1303303A1 (en) 2003-04-23
RU2004121674A (en) 2006-01-10
EP1156062A1 (en) 2001-11-21

Similar Documents

Publication Publication Date Title
AU6313301A (en) Immunomodulatory human mhc class ii antigen-binding polypeptides
GB0003790D0 (en) Medical device
EP1390390A4 (en) Human secreted proteins
NO20023063D0 (en) Shoulder Prosthesis Device
HUP0302377A3 (en) Medical device
GB0118150D0 (en) Thermophotovoltaic device
EP1351521A4 (en) Imaging device
GB0022285D0 (en) Breathing aid device
EP1383888A4 (en) Human secreted proteins
GB2399265B (en) Transilluminator
GB0218205D0 (en) Human ZZAP1 protein
TW489655U (en) Waist swinging device
GB0002665D0 (en) Human intestinal Npt2B
EP1572864A4 (en) Human serpin polypeptides
EP1318823A4 (en) Immunomodulatory preparation
EP1194439A4 (en) Human eag2
GB2364602B (en) Therapeutic device
GB2377998B (en) Imaging device
GB0110541D0 (en) Clipper aid device
GB0110746D0 (en) Button device
GB0109691D0 (en) Chair mobility device
TW487044U (en) Electromotive hopper covering device
TW461520U (en) Imaging device
AU9347701A (en) Immunomodulatory preparation
AU9481201A (en) Human nedd-1

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20021212

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

R17P Request for examination filed (corrected)

Effective date: 20021212

RIN1 Information on inventor provided before grant (corrected)

Inventor name: THOMASSEN-WOLF, ELISABETH

Inventor name: TESAR, MICHAEL

Inventor name: NAGY, ZOLTAN

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MORPHOSYS AG

Owner name: GPC BIOTECH AG

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 37/00 20060101ALN20090428BHEP

Ipc: G01N 33/53 20060101ALI20090428BHEP

Ipc: A61K 48/00 20060101ALI20090428BHEP

Ipc: A61K 39/395 20060101ALI20090428BHEP

Ipc: C07K 16/28 20060101AFI20090428BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20090512

17Q First examination report despatched

Effective date: 20090921

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1054869

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091201